Introduction {#Sec1}
============

Type-2 diabetes (T2DM) has been associated with increased fracture risk with relative risk varying from 1.2-2.2 in different studies \[[@CR1]--[@CR3]\]. Besides the increased risk of falls in T2DM patients secondary to hypoglycemia, neuropathy and retinopathy, altered bone strength is believed to play a role in this increased fracture risk. Bone mineral density (BMD), though not the best, is the most commonly used indirect measure of bone strength and fracture risk. However studies assessing BMD in T2DM have given mixed results with few suggesting normal to increased BMD in T2DM \[[@CR4],[@CR5]\] where as others documenting decreased BMD \[[@CR6]\]. Factors modulating BMD in T2DM have not been well determined. Obesity has a complex effect on BMD. Increased mechanical loading of bones along with increased anabolic effects of increased interaction of insulin with IGF-1 receptor on osteoblasts is believed to increase BMD \[[@CR7]\]. In contrast, increased sequestration of vitamin-D in obesity worsens vitamin-D deficiency impairing bone health \[[@CR8]\]. Further, increased visceral adipose tissue is believed to have a negative effect on BMD \[[@CR9]\]. Data on impact of body fat and lean mass distribution on BMD is available predominantly from post-menopausal women with or without osteoporosis \[[@CR10]--[@CR15]\]. Such studies among patients with diabetes are scanty, and are complicated by lack of adjustment for duration of diabetes, type of diabetes, use of glitazones and insulin.

Hence this study aimed to compare the total body bone mineral content (BMC) and BMD in recently diagnosed T2DM patients (\<6 months diagnosis of diabetes) with BMI matched normal controls, and to evaluate the impact of body fat and lean mass on BMC. We also planned to evaluate the role of anthropometric measurements \[waist circumference (WC), and sagittal abdominal diameter (SAD)\] in predicting central adiposity as determined by android/gynoid (A/G) ratio.

Methods {#Sec2}
=======

Stable patients of recently diagnosed T2DM (≤6 months of diagnosis), on oral anti-diabetes medications and family members of patients of T2DM, 35--55 years age, attending the diabetic clinic were considered for the study. The study duration was from August 2010 till July 2013. Patients of type-1 diabetes mellitus, secondary diabetes mellitus, monogenic diabetes, post-menopausal women, comorbid states like chronic kidney disease, liver disease, autoimmune and rheumatologic disorders, malignancies, history of insulin use, pioglitazone, drugs which interfere with BMD (oral contraceptives for more than 6 months in last 2 years, glucocorticoids, immunosuppressive agents, bisphosphonates, lithium), alcohol abuse, cigarette smoking in the last 6 months, obesity syndromes, severe obesity (BMI \> 35 kg/m^2^), pregnant women, perimenopausal or postmenopausal women were excluded. Family members of T2DM patients who had persistently normal fasting blood glucose (FBG) and 2-hour post glucose blood glucose (2hPGBG) on 75-gram glucose OGTT done twice over a period of one week were considered as normal controls. The study protocol was explained to all the considered individuals and only those who gave informed written consent were included. All subjects enrolled in this study were from the same geographical area (Gangetic Delta, Eastern India). The institutional ethics committee approved the study. Approval from the institutional ethics committee of IPGMER & SSKM hospital was obtained before initiation of the study.

The included individuals attended the outpatient services of the department after an overnight fast (12 hours). They under-went detailed clinical evaluation, anthropometric assessment blood samples collected, serum separated and stored at −80° for further analysis. Height was measured to the nearest 0.1 cm using a Charder HM200PW wall-mounted stadiometer \[calibrated using a 36″ calibration rod (Perspective Enterprise, Portage, Michigan, USA)\], and body weight was measured in light clothing to the nearest 0.1 kg using an electronic calibrated scale (Tantia, Japan, Model-HA521, Lot number-860525). Waist circumference was measured without clothes in the measurement area to the nearest 0.1 cm by a measuring tape at the level of the mid-point of the costal margin and the highest point of the iliac crest after a normal expiration. SAD was measured to the nearest 0.1 cm in the supine position with bent knees on a firm examination table after a normal expiration and without clothes in the measurement area. At the level of iliac crest (L~4--5~) SAD was measured using a sliding-beam caliper as the distance between the examination table up to the horizontal level, where the caliper arm touched the abdomen slightly but without compression. Several studies have suggested SAD to be a strong predictor of visceral adiposity \[[@CR16]--[@CR18]\].

Serum 25-hydroxy-vitamin-D (25OHD) was estimated using chemiluminescent microparticle immunoassay (Architect 25-OH Vitamin D assay, Abbott, USA). The analytical sensitivity of the assay was 4 ng/ml with a range of 9.4 ng/ml to 165.5 ng/ml. The CV of the assay ranged from 2.8-4.6%. Patients were considered vitamin D deficient if serum levels of 25OHD were \<20 ng/ml, insufficient if levels 20-30 ng/ml and sufficient if levels \>30 ng/ml \[[@CR19]\]. FBG, 2hPGBG, lipid profile, liver function, calcium, phosphorus, and creatinine were estimated using clinical chemical analyzer (Daytona, serial number-58260536, Furuno Electric, Nishnomeya, Japan). DXA was done with a GE Lunar DPX NT densitometer by the same technician to determine BMD (g/cm^2^) at the lumbar spine (L~1~-L~4~) and both neck of femur, BMC (g) total body fat (g), percentage fat mass, lean body mass (g), android fat (g) and gynoid fat (g). The lower border of android region was set at upper border of pelvis. The upper border of android region was set at a level being 20% of distance from upper border of pelvis to neck. The upper border of gynoid region was set at level below the pelvis at which the distance from the upper border of the pelvis to the upper border of gynoid region was 1.5 times the length of the android region. The lower border of the gynoid region was set at level at which the length of gynoid region was twice the length of android region \[[@CR20]\]. Quality control procedures were done as per manufacturer's recommendations. Coefficient of variation for DXA ranged from 0.7 to 3.1%.

The T2DM (Group-A) and normal individuals (Group-B) were divided into 2 groups, normal BMI (Group-A1 and Group-B1) and increased BMI (overweight to obese) (Group-A2 and Group-B2) based on BMI of \<25 and ≥25 respectively, for analysis \[[@CR20]\].

Sample size calculation {#Sec3}
-----------------------

Data on BMD in T2DM is conflicting ranging from decreased, normal to increased BMD \[[@CR4]--[@CR6]\]. In contrast, type-1 diabetes (T1DM) is uniformly associated with decreased BMD. Using DXA, osteopenia has been reported in 60% of patients with T1DM \[[@CR21]\]. Using this data, it was calculated that at least 65 T2DM patients needs to be evaluated, to keep the power of the study at 80%, type-1 error at 5% and precision either side of the proportion at 10%.

Statistical analysis {#Sec4}
--------------------

Student's *t* test was used for analysis of continuous variables. Fisher's exact test was used for binary variable. χ2 test was used for categorical variables. One-way ANOVA with post-hoc analysis was used to study outcomes where 3 or more groups were present. All values are expressed as mean ± standard deviation. P \< 0.05 has been considered statistically significant. Stepwise multiple linear regression models were used to estimate the regression coefficients for parameters showing significant bivariate association with BMC and BMD after adjusting for age, BMI and vitamin-D.

Results {#Sec5}
=======

Seventy-six recently diagnosed T2DM patients and 56 normal controls who fulfilled all criteria were included in this study, which consisted of 74 males and 58 females. Clinical and anthropometric parameters like age (44.21 ± 6.13 vs. 44.75 ± 3.9 years; P = 0.610), BMI (24.61 ± 3.30 vs. 24.70 ± 3.60 kg/m^2^; P = 0.890), waist circumference (89.56 ± 9.90 vs. 89.73 ± 10.92 cm; P = 0.933) and SAD (20.32 ± 2.27 vs. 20.28 ± 2.38 cm; P = 0.932) were comparable among patients with diabetes as compared to controls. Systolic blood pressure (131.26 ± 18.4 vs. 117.95 ± 11.57 mm of Hg; P \< 0.001) but not diastolic blood pressure (78.00 ± 9.46 vs. 75.63 ± 5.96 mm of Hg; P = 0.138) was significantly higher in patients with diabetes as compared to controls. Mean HbA1c in T2DM patients was 7.56 ± 1.27% as compared to 5.22 ± 0.14% in controls.

Of the patients with T2DM 31 had increased BMI and 45 had normal BMI. Among normal controls, 32 had increased BMI, and 24had normal BMI. Serum 25OHD was significantly lower in increased BMI individuals as compared to normal BMI individuals, both among diabetes patients and controls (Table [1](#Tab1){ref-type="table"}). Increased BMI individuals had significantly higher BMD at bilateral neck of femur and lumbar spine as compared to their normal BMI counterparts, both in T2DM patients and controls (Table [1](#Tab1){ref-type="table"}). In increased BMI individuals, BMC was significantly higher compared to their normal BMI counterparts, in T2DM but not controls (Table [1](#Tab1){ref-type="table"}). Fat mass and percent body fat were also significantly higher in increased BMI individuals as compared to their normal BMI counterparts (Table [1](#Tab1){ref-type="table"}). Lean mass was not significantly different among increased BMI individuals as compared to normal BMI individuals (Table [1](#Tab1){ref-type="table"}).Table 1**Comparison of anthropometric, biochemical, bone mineral and body fat distribution parameters in normal BMI (\<25 kg/m** ^**2**^ **) vs. increased BMI (≥25 kg/m** ^**2**^ **) individuals (type-2 diabetes and normal controls respectively)ParameterNormal BMI T** ~**2**~ **DM (n = 45) Group-A1Increased BMI T** ~**2**~ **DM (n = 31) Group-A2Normal BMI Controls (n = 24) Group-B1Increased BMI Controls (n = 32) Group-B2P value**Age (years)44.14 ± 5.8944.32 ± 6.5846.75 ± 2.02^†^42.35 ± 4.31^†^0.060Sex (Male: Female)22:2415:1518:619:130.147BMI (kg/m^2^)22.3 ± 1.67^‡^27.8 ± 2.10^‡^21.9 ± 1.50^†^28.2 ± 2.65^†^\<0.001Waist circumference (cm)84.5 ± 7.87^‡^\*96.8 ± 7.86^‡^79.3 ± 3.50^†^\*98.2 ± 6.04^†^\<0.001SAD (cm)19 ± 1.79^‡^\*21.9 ± 1.87^‡^18 ± 0.34^†^\*22.1 ± 1.40^†^\<0.001Systolic BP (mmHg)129 ± 19\*133 ± 16110 ± 2.9^†^\*128 ± 11.12^†^\<0.001Diastolic BP(mmHg)77 ± 979 ± 973 ± 4.30^†^79 ± 6.73^†^0.032FBG (mg/dl)142 ± 56\*133 ± 41^\#^81 ± 14.17\*84 ± 7.26^\#^\<0.0012 hr-PGBG (mg/dl)207 ± 78\*208 ± 70^\#^111 ± 10.75\*115 ± 13.8^\#^\<0.001HbA1c (%)7.5 ± 1.2\*7.6 ± 1.3^\#^5.2 ± 0.11\*5.2 ± 0.17^\#^\<0.00125OHD (ng/ml)23.7 ± 8.017.0 ± 12.8^\#^24.7 ± 7.49^†^11.1 ± 4.18^†\#^\<0.001Calcium (mg/dl)9.2 ± 0.479.2 ± 0.519.4 ± 0.63^†^8.9 ± 0.43^†^0.009Phosphorus (mg/dl)3.8 ± 0.43^‡^4.0 ± 0.43^‡^4.07 ± 0.424.1. ± 0.28\<0.001ALP (U/l)159 ± 82\*157 ± 55106 ± 17.49\*120 ± 40.310.001Total cholesterol (mg/dl)175 ± 41163 ± 43165 ± 16.10120 ± 40.850.395Triglyceride (mg/dl)145 ± 63167 ± 89114 ± 37.61142 ± 46.900.036LDL-C (mg/dl)105 ± 28122 ± 31^\#^104 ± 9.38115 ± 34.6^\#^0.039HDL-C (mg/dl)44 ± 6\*46 ± 1140 ± 4.09^†^\*37 ± 6.11^†^\<0.001Creatinine (mg/dl)0.86 ± 0.160.86 ± 0.120.9 ± 0.120.8 ± 0.080.286ALT (U/l)29 ± 1431 ± 1129 ± 0.2539 ± 17.550.165BMD (RF) (g/cm^2^)0.95 ± 0.125^‡^1.11 ± 0.15^‡^0.9 ± 0.11^†^1.07 ± 0.17^†^\<0.001BMD (LF) (g/cm^2^)0.97 ± 0.11^‡^\*1.13 ± 0.13^‡^0.88 ± 0.11^†^\*1.08 ± 0.18^†^\<0.001BMD (LS) (g/cm^2^)1.05 ± 0.12^‡^1.22 ± 0.16^‡^1.01 ± 0.05^†^1.14 ± 0.15^†^\<0.001% Body Fat32 ± 7.29^‡^40 ± 6.09^‡^34.08 ± 3.55^†^45.96 ± 6.42^†^\<0.001Fat mass (kg)16.29 ± 3.95^‡^27.06 ± 7.49^‡^18.17 ± 1.95^†^30.73 ± 6.85^†^\<0.001Lean mass (kg)34.72 ± 7.0936.92 ± 7.4835.82 ± 7.6636.20 ± 7.310.206BMC (kg)2.17 ± 0.32^‡^2.5 ± 0.40^‡^2.28 ± 0.36^†^2.58 ± 0.62^†^\<0.001Android/Gynoid1.17 ± 0.15\*1.19 ± 0.251.05 ± 0.09\*1.11 ± 0.10.022T~2~DM: Type 2 Diabetes Mellitus; BMI: Body Mass Index; SAD: Sagittal Abdominal Diameter; BP: blood pressure; FBG: Fasting blood glucose; 2 h-PGBG: 2-hour post-glucose blood glucose; HbA1c: glycosylated hemoglobin; 25OHD: 25-hydroxy-vitamin-D; LDL: Low Density Lipoprotein Cholesterol; HDL: High Density Lipoprotein Cholesterol; BMD: Bone Mineral Density; BMC: Bone Mineral Content; ALT: alanine aminotransferase; LS: lumbar spine; LF: left femur; RF: right femur; all values expressed as mean ± standard deviation; P-value calculated by one way ANOVA with least significant difference post-hoc analysis; P \< 0.05 considered statistically significant; ^‡^: P \< 0.05 when comparing normal BMI with increased BMI diabetes patients; ^†^: P \< 0.05 when comparing normal BMI with increased BMI controls; \*: P \< 0.05 when comparing normal BMI diabetes patients with normal BMI controls; ^\#^: P \< 0.05 when comparing increased BMI diabetes patients with increased BMI controls.

Normal BMI diabetes patients had higher waist circumference and SAD, as compared to normal BMI controls, which approached statistical significance (Table [1](#Tab1){ref-type="table"}). BMD left femur was significantly higher in normal BMI T2DM patients as compared to controls (Table [1](#Tab1){ref-type="table"}). Normal BMI T2DM patients had higher Android to Gynoid fat (A/G) ratio, which approached statistical significance (Table [1](#Tab1){ref-type="table"}). BMD lumbar spine was significantly higher in increased BMI T2DM patients as compared to increased BMI normal controls (Table [1](#Tab1){ref-type="table"}). Fat mass and percent body fat were significantly higher in increased BMI controls as compared to increased BMI diabetes patients (Table [1](#Tab1){ref-type="table"}). Normal BMI diabetes patients had decreased lean mass as compared to normal BMI controls, but not statistically significant.

A significantly greater proportion of females had diabetes as compared to males (67.24% vs. 50%) (Table [2](#Tab2){ref-type="table"}). Males had significantly higher waist circumference and SAD in spite of comparable BMI (Table [2](#Tab2){ref-type="table"}). Serum 25OHD was significantly lower, serum LDL-C and HDL-C were significantly higher in females. BMD right femur, BMC, lean mass and A/G ratios were significantly higher in males, where as fat mass and percent body fat were significantly higher in females (Table [2](#Tab2){ref-type="table"}).Table 2**Comparison of anthropometric, biochemical, bone mineral and body fat distribution parameters in males vs. femalesParameterMales (n = 74)Females (n = 58)P-value**Diabetes: Normal controls37:3739:190.047Age (years)46.15 ± 1.0942.32 ± 5.160.001BMI (kg/m^2^)24.45 ± 3.3524.82 ± 3.510.57Waist circumference (cm)92.56 ± 9.786.22 ± 9.150.001SAD (cm)20.88 ± 2.2919.67 ± 2.190.005Systolic BP (mmHg)123.91 ± 16.04129.08 ± 18.880.111Diastolic BP(mmHg)75.61 ± 7.0478.65 ± 9.480.048FBG (mg/dl)109.48 ± 42.95126.10 ± 54.050.0712 hr-PGBG (mg/dl)156.03 ± 65.45193.92 ± 79.480.008HbA1c (%)6.39 ± 1.526.92 ± 1.460.06725OHD (ng/ml)24.01 ± 11.0220.06 ± 8.460.043Calcium (mg/dl)9.31 ± 0.609.09 ± 0.400.068Phosphorus (mg/dl)3.68 ± 0.543.59 ± 0.460.411ALP (U/l)130.60 ± 70.94139.12 ± 42.640.529Total cholesterol (mg/dl)164.65 ± 29.78178.77 ± 44.010.062Triglyceride (mg/dl)150.63 ± 60.81138.58 ± 60.770.358LDL-C (mg/dl)99.48 ± 22.60111.90 ± 32.230.029HDL-C (mg/dl)39.48 ± 8.7945.49 ± 7.680.001Creatinine (mg/dl)0.93 ± 0.160.81 ± 0.120.001ALT (U/l)33.11 ± 13.1131.12 ± 15.420.581BMD (RF) (g/cm^2^)1.04 ± 0.190.97 ± 0.120.022BMD (LF) (g/cm^2^)1.05 ± 0.20.99 ± 0.120.087BMD (LS) (g/cm^2^)1.12 ± 0.161.10 ± 0.170.441% Body Fat32.53 ± 6.3641.21 ± 6.190.001Fat mass (kg)20.49 ± 6.5823.39 ± 8.780.052Lean mass (kg)41.43 ± 5.5430.44 ± 4.170.001BMC (kg)2.65 ± 0.502.08 ± 0.270.001Android/Gynoid1.25 ± 0.171.04 ± 0.130.001BMI: Body Mass Index; SAD: Sagittal Abdominal Diameter; BP: blood pressure; FBG: Fasting blood glucose; 2 h-PGBG: 2-hour post-glucose blood glucose; HbA1c: glycosylated hemoglobin; 25OHD: 25-hydroxy-vitamin-D; LDL: Low Density Lipoprotein Cholesterol; HDL: High Density Lipoprotein Cholesterol; BMD: Bone Mineral Density; BMC: Bone Mineral Content; ALT: alanine aminotransferase; LS: lumbar spine; LF: left femur; RF: right femur; all values expressed as mean ± standard deviation; P-value calculated by unpaired t-test; P \< 0.05 considered statistically significant.

Lean mass had a stronger positive correlation with whole body BMC and BMD at different sites as compared to fat mass, after adjusting for age, BMI and 25OHD, both in normal individuals and patients with diabetes (Table [3](#Tab3){ref-type="table"}). BMI, SAD and A/G ratio also had a positive correlation with BMC and BMD at different sites (Table [3](#Tab3){ref-type="table"}). Percent body fat had negative correlation with BMC and BMD at different sites. 25OHD had positive correlation with BMC and BMD at different sites only in normal controls (Table [3](#Tab3){ref-type="table"}). Waist circumference most strongly correlated with A/G ratio (r = 0.56; P \< 0.001 and r = 0.55; P \< 0.001), followed by SAD (r = 0.49; P \< 0.001 and r = 0.42; P = 0.007), after adjusting for BMI, in patients with diabetes and controls respectively.Table 3**Correlation between bone mineral density at different sites and total bone mineral content (BMC) with anthropometric parameters, and body fat and lean mass distribution parameters in diabetes patients and normal controls, after adjusting for age, body mass index (BMI) and 25-hydroxyvitamin-DParameterBMD (RF)BMD (LF)BMD (LS)BMC**T2DM patients(n = 74)Age0.110.100.10.3\*BMI0.4\*0.32 ^\#^0.29\*0.34^\#^25OHD0.10.10.10.18HbA1c0.080.130.13−0.03SAD0.270.27−0.160.38^\#^Fat Mass0.180.170.10.24Lean Mass0.38\*0.35\*0.050.42^\#^% body fat−0.31\*−0.32\*−0.12−0.34^\#^A/G Ratio0.28\*0.27\*−0.010.39^\#^Normal Controls (n = 58)Age−0.16−0.25−0.320.14BMI0.350.260.110.30\*25OHD0.33^\#^0.35^\#^0.35^\#^0.21^\#^HbA1c0.180.160.160.10SAD0.270.36\*0.41\*0.37\*Fat Mass0.120.050.140.21Lean Mass0.35\*0.33\*0.44^\#^0.31\*% body fat−0.29\*−0.24\*−0.25\*−0.33^\#^A/G Ratio0.31^\#^0.28\*0.21\*0.33^\#^T2DM: Type-2 diabetes; BMD: bone mineral density; RF: right femur; LF: left femur; LS: lumbo-sacral spine; BMC: total body bone mineral content; SAD: Sagittal abdominal diameter; A/G: Android/Gynoid fat ratio; Pearson's correlation coefficient calculated; value in parentheses represent P-value; P \< 0.05 considered statistically significant; \*: P \< 0.05; ^\#^: P \< 0.001.

For parameters showing significant bivariate association with BMC and BMD at different sites (BMI, SAD, lean mass, fat mass, percent body fat and A/G ratio), generalized linear models were constructed to determine their potential independent contributions to BMC and BMD after adjusting for age, BMI, 25OHD and HbA1c in Model 1, and age, sex, BMI and 25OHD in Model 2. Multiple linear regression analysis revealed that lean mass was the strongest predictor of whole body BMC followed by fat mass, both in normal individuals and patients with diabetes (Table [4](#Tab4){ref-type="table"}). Percent body fat, SAD and A/G ratio were predictive of BMC only in normal individuals. Fat mass was the best predictor of BMC in males where as lean mass was the best predictor of BMC in females (Table [4](#Tab4){ref-type="table"}). Similar predictions were not observed for BMD at different sites.Table 4**Multiple linear regressions showing the effect of body fat distribution parameters on bone mineral content (BMC) after adjustment for variables in different modelsMale (n = 74)Female (n = 58)Normal Individuals (n = 56)Type-2 diabetes (n = 76)Model-1Model-1Model-2Model-2βP-valueP-valueβP-valueΒP-value**Total body BMCSAD−0.0480.5650.1410.4220.1850.010.0280.727Lean mass0.1300.1500.2240.0080.1770.010.2070.001Fat mass0.1120.0320.0540.4220.1060.0330.1510.012Tissue fat percent0.0850.5110.0600.6340.1710.020.0910.336A/G ratio0.0730.223−0.0190.6350.1760.051−0.1160.158Stepwise regression analysis was done adjusting for the following variables: Model-1: adjusted for age, BMI, vitamin-D and HbA1c; Model-2: adjusted for age, sex, BMI and vitamin-D; BMC: bone mineral content; SAD: sagittal abdominal diameter; A/G ratio: android/gynoid ratio.

Discussion {#Sec6}
==========

Lower vitamin-D in increased BMI individuals in our study can be explained by the increased sequestration of vitamin-D in the adipose tissue \[[@CR8]\]. Adipocytes are believed to have some role in vitamin-D destruction and it has been suggested that vitamin-D deficiency per se leads to worsening of obesity by directly stimulating lipogenesis and by inhibiting catecholamine induced lipolysis \[[@CR22],[@CR23]\]. Polymorphisms in vitamin D gene and its receptor have been linked to obesity \[[@CR24]--[@CR26]\]. The lower vitamin-D levels in increased BMI controls in our study as compared to increased BMI diabetes patients can be explained by the higher body fat content in increased BMI controls.

Our study showed that patients with diabetes (normal and increased BMI) had higher BMC and BMD as compared to normal individuals. Similarly individuals with increased BMI (with or without diabetes), in spite of a lower vitamin-D state, had higher BMC and BMD as compared to normal BMI individuals. This is similar to observations from Rotterdam study that noted that BMD at both lumbar spine and femoral neck was substantially higher in patients with diabetes as compared to normal individuals, even after adjusting for confounding variables \[[@CR4]\]. The Rancho Bernardo study also documented increased BMD in women with diabetes as compared to normal individuals \[[@CR27]\]. Increased anabolic effect of hyperinsulinemia in T2DM may have some role in the increased BMC and BMD in T2DM \[[@CR7]\]. Increased mechanical loading of the bones secondary to obesity may explain the increased BMC and BMD in obesity. Also increased aromatase activity of adipose tissue may also contribute to this increased BMC and BMD in obesity \[[@CR28]\]. De Laet et al., in a meta-analysis of 12 multinational cohorts comprising nearly 60,000 adult subjects, showed that independent of sex, those with BMI \> 25 kg/m^2^ had significantly higher BMD and lower rates of hip, osteoporotic, and all fractures \[[@CR28]\].

Waist circumference and SAD (measures of central obesity) were almost significantly higher in normal BMI T2DM and compared to BMI matched controls. Our study showed that WC correlated most strongly with A/G ratio followed by SAD. Hence WC may be a better predictor of central adiposity as compared to SAD. Increased A/G ratio, the measure of central adiposity was almost significantly higher in normal BMI diabetes patients as compared to controls. Similarly decreased total body fat along with comparable WC and SAD in increased BMI diabetes patients as compared to increased BMI controls is suggestive of a higher percentage of visceral adiposity in increased BMI diabetes patients. Increased A/G ratio in increased BMI diabetes supports this hypothesis. Hence diabetes (normal or increased BMI) is associated with increased central adiposity. Truncal fat mass has been shown to correlate strongly with insulin resistance in mildly overweight new onset diabetes \[[@CR29]\]. In our study A/G ratio had a positive correlation with BMC and BMD at different sites both in diabetes patients and normal controls. This is in accordance with previous observations of subjects with android fat distribution having higher BMD as compared to those with gynoid distribution \[[@CR30]\]. It is believed that increased insulin resistance associated with increased central obesity leads to decreased sex-hormone binding globulin, leading to increased free testosterone and estradiol promoting bone formation \[[@CR30]\]. Also it is believed that increased android fat leads to increased mechanical loading of femur leading to increased BMD \[[@CR30]\]. It must be clarified that central adiposity is constituted by visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Increased SAT is believed to have a positive effect on BMD, where as increased VAT is believed to have a negative effect on BMD \[[@CR9]\]. Increased VAT is associated with increased circulating inflammatory cytokines and chemokines, altered profile of leptin and adiponectin leading to increased osteoclast activation and bone loss \[[@CR9]\]. However VAT and SAT were not separately evaluated in our study and is one of the limitations of this study. Use of DXA is limited by its ability to measure only the total body fat and it cannot differentiate between VAT and SAT. Another limitation of this study is its cross-sectional nature and lack of measurement of cytokines and adipokines.

Our study showed that increase in fat mass is associated with increased BMC both in diabetes and normal individuals. This is in accordance with recent reports from India, Holland and Korea showing increased fat mass having a positive effect on BMD at all sites in normal men and women \[[@CR31]\].The most important observation of this study is the strongest correlation of lean mass with BMC and BMD both in normal individuals and patients with diabetes, with regression analysis confirming lean mass to be the strongest predictor of BMC, after adjusting for age, sex, BMI and vitamin-D. Increased lean mass perhaps results in more mechanical loading of body as compared to fat mass, resulting in a greater increase in bone mass \[[@CR32],[@CR33]\]. It has been suggested that bone adapts more to dynamic muscle load than to static load, explaining the stronger effect of lean mass over fat mass on BMC \[[@CR34]\]. This explains the beneficial effect of physical activity on bone health. Isolated increase in fat mass (adiposity) results in lesser dynamic loading of bones secondary to decreased physical activity. Additional benefits of increased lean mass include prevention of falls, thus decreasing fracture risk. Increased occurrence of diabetes among females in our study cohort explains the higher blood glucose parameters and HbA1c in females. Central obesity was more common in males, who also had higher BMC and lower fat mass and body fat percent, supporting the previous hypothesis (vide supra).

To the best of our knowledge, this is the first study to report BMC, BMD and body composition changes in normal and increased BMI T2DM patients comparing it with BMI matched controls. Our study showed that both T2DM and increase in BMI are associated with increased BMC and BMD, with lean mass having the strongest impact on BMC. Further prospective studies are suggested to document the beneficial effects of increased physical activity on increased lean mass, and its impact on long term fall and fracture outcomes in diabetes.

Conclusions {#Sec7}
===========

Both increased BMI and T2DM are associated with increased BMC and BMD at different sites, with lean mass having the strongest impact on BMC in normal individuals and patients with diabetes followed by fat mass. Males have higher BMC and BMD as compared to females, likely due to greater lean mass, A/G ratio, along with lesser fat mass and percent body fat. Fat mass was the best predictor of BMC in males where as lean mass was the best predictor of BMC in females.
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